{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:23:20Z","timestamp":1768533800465,"version":"3.49.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T00:00:00Z","timestamp":1583798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0229691","type":"journal-article","created":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T13:51:15Z","timestamp":1583848275000},"page":"e0229691","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-2589","authenticated-orcid":true,"given":"Brett D.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Kunimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjani","family":"Somayaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"issue":"10","key":"pone.0229691.ref001","doi-asserted-by":"crossref","first-page":"e3426","DOI":"10.1371\/journal.pone.0003426","article-title":"Detection and Molecular Characterization of 9000-Year-Old Mycobacterium tuberculosis from a Neolithic Settlement in the Eastern Mediterranean","volume":"3","author":"I Herkovitz","year":"2008","journal-title":"PLoS One"},{"key":"pone.0229691.ref002","unstructured":"Global Tuberculosis Report [Internet]. World Health Organization. 2018 [cited 2018 Aug 7]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/259366\/1\/9789241565516-eng.pdf?ua=1"},{"issue":"4","key":"pone.0229691.ref003","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"RS Wallis","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pone.0229691.ref004","first-page":"1","volume-title":"Canadian Tuberculosis Standards","author":"R Long","year":"2014"},{"key":"pone.0229691.ref005","unstructured":"Drug-Resistant TB: Global Situation [Internet]. World Health Organization. 2018 [cited 2018 Aug 9]. Available from: http:\/\/www.who.int\/tb\/areas-of-work\/drug-resistant-tb\/global-situation\/en\/"},{"key":"pone.0229691.ref006","first-page":"1","volume-title":"Guidelines for Treatment of Tuberculosis","year":"2010"},{"key":"pone.0229691.ref007","first-page":"1","volume-title":"WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis","year":"2018"},{"issue":"2","key":"pone.0229691.ref008","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1473-3099(16)30407-8","article-title":"Soolingen D Van, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis","volume":"17","author":"M Gegia","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"pone.0229691.ref009","first-page":"236","article-title":"Tuberculosis: Drug resistance in Canada\u2013 2012","volume":"43","author":"V Gallant","year":"2017","journal-title":"Can Commu Dis Rep"},{"issue":"4","key":"pone.0229691.ref010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"K Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"pone.0229691.ref011","first-page":"53","article-title":"Molecular Biology of Drug Resistance in Mycobacterium Tuberculosis","volume":"374","author":"T Smith","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"pone.0229691.ref012","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1513\/AnnalsATS.201711-885ED","article-title":"Isoniazid Monoresistance: A precursor to Multidrug-Resistant Tuberculosis?","volume":"15","author":"M O\u2019Donnell","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"pone.0229691.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000150","article-title":"Standardized treatment of active tuberculosis in patients with previous treatment and\/or with mono-resistance to isoniazid: A systematic review and meta-analysis","volume":"6","author":"D Menzies","year":"2009","journal-title":"PLoS Med"},{"issue":"4","key":"pone.0229691.ref014","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"F Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"pone.0229691.ref015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmi.2014.08.008","article-title":"Treatment outcome of patients with isoniazid mono-resistant tuberculosis","volume":"21","author":"JY Chien","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pone.0229691.ref016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/qjmed\/hcu139","article-title":"Isoniazid-resistant tuberculosis in Birmingham, United Kingdom, 1999\u20132010","volume":"108","author":"M Munang","year":"2015","journal-title":"QJM"},{"issue":"1","key":"pone.0229691.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2706-0","article-title":"Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada","volume":"17","author":"K Romanowski","year":"2017","journal-title":"BMC Infect Dis"},{"key":"pone.0229691.ref018","unstructured":"Tuberculosis: Center for Disease Control and Prevention [Internet]. 2017 [cited 2019 Aug 28]. Available from: https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/statistics\/tbtrends.htm"},{"key":"pone.0229691.ref019","first-page":"1","volume-title":"Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment","year":"2019"},{"key":"pone.0229691.ref020","first-page":"9","volume-title":"Definitions and reporting framework for tuberculosis\u2013 2013 revision","year":"2013"},{"key":"pone.0229691.ref021","volume-title":"Stata Statistical Software","author":"StataCorp","year":"2017"},{"key":"pone.0229691.ref022","volume-title":"R: A language and environment for statistical computing","author":"Foundation for Statistical Computing R","year":"2017"},{"key":"pone.0229691.ref023","unstructured":"Population estimates, quarterly [Internet]. Statistics Canada\u2014Table 17\u201310-0009-01. 2019 [cited 2019 Jul 1]. Available from: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000901"},{"issue":"2","key":"pone.0229691.ref024","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1086\/595689","article-title":"Clinical Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis","volume":"48","author":"A Cattamanchi","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pone.0229691.ref025","doi-asserted-by":"crossref","first-page":"934","DOI":"10.5588\/ijtld.12.0782","article-title":"Hepatotoxicity due to first-line anti-tuberculosis drugs: A five-year experience in a Taiwan medical centre","volume":"17","author":"CC Shu","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"pone.0229691.ref026","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review","volume":"23","author":"A Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"10","key":"pone.0229691.ref027","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of Drug-Resistant Tuberculosis. An Official ATS\/CDC\/ERS\/IDSA Clinical Practice Guideline","volume":"200","author":"P Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"pone.0229691.ref028","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jinf.2010.03.017","article-title":"Isoniazid-resistant tuberculosis in Denmark: Mutations, transmission and treatment outcome","volume":"60","author":"D Bang","year":"2010","journal-title":"J Infect"},{"issue":"1","key":"pone.0229691.ref029","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.01377-15","article-title":"Treatment Outcomes with Fluoroquinolone-Containing Regimens for","volume":"60","author":"H Lee","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pone.0229691.ref030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0206658","article-title":"Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012\u20132014","volume":"13","author":"JG Cornejo Garcia","year":"2018","journal-title":"PLoS One"},{"key":"pone.0229691.ref031","article-title":"Fluoroquinolones and isoniazid resistant TB: implications for the 2018 WHO guidance","author":"HR Stagg","year":"2019","journal-title":"Eur Respir J"},{"issue":"4","key":"pone.0229691.ref032","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1183\/13993003.01494-2019","article-title":"Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?","volume":"54","author":"R Diel","year":"2019","journal-title":"Eur Respir J"},{"key":"pone.0229691.ref033","first-page":"1","article-title":"Mechanisms of Action and Resistance","author":"DC Hooper","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"pone.0229691.ref034","unstructured":"Fluoroquinolone Antimicrobial Drugs Information [Internet]. FDA Drug Information. 2018 [cited 2019 Jul 27]. Available from: https:\/\/www.fda.gov\/drugs\/information-drug-class\/fluoroquinolone-antimicrobial-drugs-information"},{"issue":"11","key":"pone.0229691.ref035","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2019.07.035","article-title":"Oral fluoroquinolones and risk of mitral and aortic regurgitation","volume":"74","author":"M Etminan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"pone.0229691.ref036","article-title":"The effectiveness and safety of fluoroquinolone-containing regimen as a first-line treatment for drug-sensitive pulmonary tuberculosis: A systematic review and meta-analysis","volume":"11","author":"HW Lee","year":"2016","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,10]],"date-time":"2020-03-10T13:51:36Z","timestamp":1583848296000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229691"}},"subtitle":[],"editor":[{"given":"Kevin","family":"Schwartzman","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0229691","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]}}}